In October 2023, Nykode completed a private placement round of approx NOK 505 million and this week, the company revealed that CapitalGroup, one of the world’s ten largest capital management funds, represented ca 40% of the financing round.
This places CapitalGroup as the company’s sixth largest investor.
Read more: Nykode Therapeutics raises NOK 505 million
“Scientific and strategic interactions with competent capital partners such as CapitalPartners, validates Nykodes technology, clinical data and strategy. We are very proud to have attracted Capital Partners as a competent and long term investor for the next phase of building the company and its pipeline,” says Agnete Fredriksen, Chief Business Officer and Co-Founder in Nykode.
This is an example to follow for the growing pipeline of Norwegian biotech companies, coming from the strong scientific milieus in Norway in areas such as immunology and oncology.”
“Nykode has secured solid validation of its platform, pipeline and strategic choices over the last years, both from strategic partners and solid, competent investors. This is an example to follow for the growing pipeline of Norwegian biotech companies, coming from the strong scientific milieus in Norway in areas such as immunology and oncology. The Norwegian strength in combining existing strongholds to develop new ideas, an understanding of future global needs and a true pioneering stamina, has resulted in several exciting companies with a solid scientific base. We look forward to following Nykode’s further development,” says Hanne Mette Kristensen, CEO of The Life Science Cluster.
Photo of Michael Engsig, CEO, and Agnete Fredriksen, CBO and co-founder, Nykode
